$0.40
-0.01 (-2.34%)
Open$0.42
Previous Close$0.41
Day High$0.43
Day Low$0.39
52W High$1.24
52W Low$0.30
Volume—
Avg Volume356.1K
Market Cap15.56M
P/E Ratio—
EPS$-0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+837.7% upside
Current
$0.40
$0.40
Target
$3.76
$3.76
$2.62
$3.76 avg
$5.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.23M | 7.84M | 7.68M |
| Net Income | -32,411,039 | -2,005,672 | -1,738,578 |
| Profit Margin | -619.8% | -25.6% | -22.6% |
| EBITDA | -32,983,474 | -2,263,216 | -2,551,790 |
| Free Cash Flow | — | -1,406,564 | -1,071,377 |
| Rev Growth | — | +12.8% | +0.1% |
| Debt/Equity | 0.06 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |